Cardiac myocyte-fibroblast interactions and the coronary vasculature

Journal of Cardiovascular Translational Research

Volumn 5, Issue 6, 2012, Pages 783-793

  Bowers, Stephanie L K ^a,b,c   Baudino, Troy A ^a,b,c  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c Central Texas Veterans Health Administration   (United States)

Author keywords

Cardiac fibroblast; Cardiovascular; Cell cell interactions; EMT; EndoMT; Endothelial cell; Fibrosis; Myocyte; Vascular remodeling

Indexed keywords

ANGIOTENSIN II; CYTOKINE; GROWTH FACTOR; MICRORNA; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL COMMUNICATION; CELL INTERACTION; CELL TRANSFORMATION; CORONARY BLOOD VESSEL; ENDOTHELIAL MESENCHYMAL TRANSFORMATION; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FORCE; HEART INJURY; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; MACROPHAGE; MORPHOLOGY; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE ENGINEERING; ANGIOGENESIS; ANIMAL; FIBROSIS; HEART DISEASE; METABOLISM; PATHOLOGY; REGENERATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL COMMUNICATION; CORONARY VESSELS; FIBROBLASTS; FIBROSIS; HEART DISEASES; HUMANS; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATION; SIGNAL TRANSDUCTION; TISSUE ENGINEERING;

EID: 84878182000     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9407-2     Document Type: Article

References (110)

1. Waters, S. L.; Alastruey, J.; Beard, D. A.; Bovendeerd, P. H.; Davies, P. F.; Jayaraman, G.; Jensen, O. E.; Lee, J.; Parker, K. H.; Popel, A. S.; Secomb, T. W.; Siebes, M.; Sherwin, S. J.; Shipley, R. J.; Smith, N. P.; & van de Vosse, F. N. (2011). Theoretical models for coronary vascular biomechanics: Progress & challenges. Progress in Biophysics and Molecular Biology, 104(1-3), 49-76. doi: 10.1016/j.pbiomolbio.2010.10.001.
2. Davies, P. F. (2009). Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nature Clinical Practice. Cardiovascular Medicine, 6(1), 16-26. doi: 10.1038/ncpcardio1397.
3. Ting, L. H.; Jahn, J. R.; Jung, J. I.; Shuman, B. R.; Feghhi, S.; Han, S. J.; Rodriguez, M. L.; & Sniadecki, N. J. (2012). Flow mechanotransduction regulates traction forces, intercellular forces, and adherens junctions. American Journal of Physiology-Heart and Circulatory Physiology, 302(11), H2220-H2229. doi: 10.1152/ajpheart.00975.2011.
4. Takeda, N.; & Manabe, I. (2011). Cellular interplay between cardiomyocytes and nonmyocytes in cardiac remodeling. International Journal Inflammation, 2011, 535241. doi: 10.4061/2011/535241.
5. Tian, Y.; & Morrisey, E. E. (2012). Importance of myocyte-nonmyocyte interactions in cardiac development and disease. Circulation Research, 110(7), 1023-1034. doi: 10.1161/CIRCRESAHA.111.243899.
6. Holmes, J. W.; Borg, T. K.; & Covell, J. W. (2005). Structure and mechanics of healing myocardial infarcts. Annual Review of Biomedical Engineering, 7, 223-253.
7. Kohl, P.; & Camelliti, P. (2011). Fibroblast-myocyte connections in the heart. Heart Rhythm. doi: 10.1016/j.hrthm.2011.10.002.
8. Rohr, S. (2012). Arrhythmogenic implications of fibroblast-myocyte interactions. Circulation. Arrhythmia and Electrophysiology, 5(2), 442-452. doi: 10.1161/CIRCEP.110.957647.
9. Sussman, M. A.; McCulloch, A.; & Borg, T. K. (2002). Dance band on the Titanic: Biomechanical signaling in cardiac hypertrophy. Circulation Research, 91(10), 888-898.
10. Camelliti, P.; Borg, T. K.; & Kohl, P. (2005). Structural and functional characterisation of cardiac fibroblasts. Cardiovascular Research, 65(1), 40-51. doi: 10.1016/j.cardiores.2004.08.020.
11. Young, A. A.; Legrice, I. J.; Young, M. A.; & Smaill, B. H. (1998). Extended confocal microscopy of myocardial laminae and collagen network. Journal of Microscopy, 192(Pt 2), 139-150.
12. Bowers, S. L.; Borg, T. K.; & Baudino, T. A. (2010). The dynamics of fibroblast-myocyte-capillary interactions in the heart. Annals of the New York Academy of Sciences, 1188, 143-152. doi: 10.1111/j.1749-6632.2009.05094.x.
13. Liu, H.; Chen, B.; & Lilly, B. (2008). Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1. Angiogenesis, 11(3), 223-234.
14. Burlew, B. S.; & Weber, K. T. (2002). Cardiac fibrosis as a cause of diastolic dysfunction. Herz, 27(2), 92-98.
15. Manabe, I.; Shindo, T.; & Nagai, R. (2002). Gene expression in fibroblasts and fibrosis: Involvement in cardiac hypertrophy. Circulation Research, 91(12), 1103-1113.
16. Borg, T. K.; & Caulfield, J. B. (1981). The collagen matrix of the heart. Federation Proceedings, 40(7), 2037-2041.
17. Weber, K. T.; Brilla, C. G.; Campbell, S. E.; Zhou, G.; Matsubara, L.; & Guarda, E. (1992). Pathologic hypertrophy with fibrosis: The structural basis for myocardial failure. Blood Pressure, 1(2), 75-85.
18. Weber, K. T.; Sun, Y.; & Diez, J. (2008). Fibrosis: A living tissue and the infarcted heart. Journal of the American College of Cardiology, 52(24), 2029-2031.
19. Sabbah, H. N.; Sharov, V. G.; Lesch, M.; & Goldstein, S. (1995). Progression of heart failure: A role for interstitial fibrosis. Molecular and Cellular Biochemistry, 147(1-2), 29-34.
20. Cleutjens, J. P.; Blankesteijn, W. M.; Daemen, M. J.; & Smits, J. F. (1999). The infarcted myocardium: Simply dead tissue, or a lively target for therapeutic interventions. Cardiovascular Research, 44(2), 232-241.
21. Xiao, J.; Jiang, H.; Zhang, R.; Fan, G.; Zhang, Y.; Jiang, D.; & Li, H. (2012). Augmented cardiac hypertrophy in response to pressure overload in mice lacking ELTD1. PLoS One, 7(5), e35779. doi: 10.1371/journal.pone. 0035779PONE-D-11-25153.
22. Souders CA, T.K. B, I. B, T.A. B (2012) Pressure overload induces early morphological changes in the heart. American Journal of Pathology In Press
23. Baudino, T. A.; Carver, W.; Giles, W.; & Borg, T. K. (2006). Cardiac fibroblasts: Friend or foe? American Journal of Physiology - Heart and Circulatory Physiology, 291(3), H1015-H1026. doi: 10.1152/ajpheart.00023.2006.
24. Gaudesius, G.; Miragoli, M.; Thomas, S. P.; & Rohr, S. (2003). Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin. Circulation Research, 93(5), 421-428. doi: 10.1161/01.RES.0000089258.40661.0C01.RES.0000089258.40661.0C.
25. Brutsaert, D. L. (2003). Cardiac endothelial-myocardial signaling: Its role in cardiac growth, contractile performance, and rhythmicity. Physiological Reviews, 83(1), 59-115. doi: 10.1152/physrev.00017.2002.
26. Kakkar, R.; & Lee, R. T. (2010). Intramyocardial fibroblast myocyte communication. Circulation Research, 106(1), 47-57. doi: 10.1161/CIRCRESAHA.109. 207456.
27. Ottaviano, F. G.; & Yee, K. O. (2011). Communication signals between cardiac fibroblasts and cardiac myocytes. Journal of Cardiovascular Pharmacology, 57(5), 513-521. doi: 10.1097/FJC.0b013e31821209ee.
28. Graham, H. K.; Horn, M.; & Trafford, A. W. (2008). Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiologica (Oxford, England), 194(1), 3-21.
29. Saffitz, J. E.; Hames, K. Y.; & Kanno, S. (2007). Remodeling of gap junctions in ischemic and nonischemic forms of heart disease. Journal of Membrane Biology, 218(1-3), 65-71. doi: 10.1007/s00232-007-9031-2.
30. Zamilpa, R.; & Lindsey, M. L. (2010). Extracellular matrix turnover and signaling during cardiac remodeling following MI: Causes and consequences. Journal of Molecular and Cellular Cardiology, 48(3), 558-563. doi: 10.1016/j.yjmcc.2009.06.012.
31. Esper, R. J.; Nordaby, R. A.; Vilarino, J. O.; Paragano, A.; Cacharron, J. L.; & Machado, R. A. (2006). Endothelial dysfunction: A comprehensive appraisal. Cardiovascular Diabetology, 5, 4. doi: 10.1186/1475-2840-5-4.
32. Pinsky, D. J.; Patton, S.; Mesaros, S.; Brovkovych, V.; Kubaszewski, E.; Grunfeld, S.; & Malinski, T. (1997). Mechanical transduction of nitric oxide synthesis in the beating heart. Circulation Research, 81(3), 372-379.
33. Kai, H.; Mori, T.; Tokuda, K.; Takayama, N.; Tahara, N.; Takemiya, K.; Kudo, H.; Sugi, Y.; Fukui, D.; Yasukawa, H.; Kuwahara, F.; & Imaizumi, T. (2006). Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertension Research, 29(9), 711-718. doi: 10.1291/hypres.29.711.
34. Seddon, M.; Shah, A. M.; & Casadei, B. (2007). Cardiomyocytes as effectors of nitric oxide signalling. Cardiovascular Research, 75(2), 315-326. doi: 10.1016/j.cardiores.2007.04.031.
35. Harrison, D. G.; Widder, J.; Grumbach, I.; Chen, W.; Weber, M.; & Searles, C. (2006). Endothelial mechanotransduction, nitric oxide and vascular inflammation. Journal of Internal Medicine, 259(4), 351-363. doi: 10.1111/j.1365-2796.2006.01621.x.
36. Droge, W. (2002). Free radicals in the physiological control of cell function. Physiological Reviews, 82(1), 47-95. doi: 10.1152/physrev.00018.2001.
37. Touyz, R. M. (2004). Reactive oxygen species and angiotensin II signaling in vascular cells - Implications in cardiovascular disease. Brazilian Journal of Medical and Biological Research, 37(8), 1263-1273.
38. Touyz, R. M.; & Briones, A. M. (2011). Reactive oxygen species and vascular biology: Implications in human hypertension. Hypertension Research, 34(1), 5-14. doi: 10.1038/hr.2010.201.
39. Pan, H.; Xu, X.; Hao, X.; & Chen, Y. (2012). Changes of myogenic reactive oxygen species and interleukin-6 in contracting skeletal muscle cells. Oxidative Medicine and Cellular Longevity, 2012, 145418. doi: 10.1155/2012/145418.
40. Banerjee I, Fuseler, JW, Souders CA, Bowers SLK, Baudino TA (2009) The role of interleukin-6 in the formation of the coronary vasculature. Microscopy and Microanalysis In Press
41. Banerjee, I.; Fuseler, J. W.; Intwala, A. R.; & Baudino, T. A. (2009). IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. American Journal of Physiology - Heart and Circulatory Physiology, 296(5), H1694-H1704. doi: 10.1152/ajpheart.00908.2008.
42. Goldsmith, E. C.; & Borg, T. K. (2002). The dynamic interaction of the extracellular matrix in cardiac remodeling. Journal of Cardiac Failure, 8(6 Suppl), S314-S318.
43. Sacharidou, A.; Stratman, A. N.; & Davis, G. E. (2012). Molecular mechanisms controlling vascular lumen formation in three-dimensional extracellular matrices. Cells, Tissues, Organs, 195(1-2), 122-143. doi: 10.1159/000331410.
44. Stratman, A. N.; & Davis, G. E. (2012). Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: Influence on vascular tube remodeling, maturation, and stabilization. Microscopy and Microanalysis, 18(1), 68-80. doi: 10.1017/S1431927611012402.
45. Liu, H.; Kennard, S.; & Lilly, B. (2009). NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. Circulation Research, 104(4), 466-475. doi: 10.1161/CIRCRESAHA.108.184846.
46. Stratman, A. N.; Malotte, K. M.; Mahan, R. D.; Davis, M. J.; & Davis, G. E. (2009). Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood, 114(24), 5091-5101. doi: 10.1182/blood-2009-05-222364.
47. Tomanek, R. J.; Hansen, H. K.; & Christensen, L. P. (2008). Temporally expressed PDGF and FGF-2 regulate embryonic coronary artery formation and growth. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(7), 1237-1243. doi: 10.1161/ATVBAHA.108.166454.
48. Sun, Y.; Kiani, M. F.; Postlethwaite, A. E.; & Weber, K. T. (2002). Infarct scar as living tissue. Basic Research in Cardiology, 97(5), 343-347. doi: 10.1007/s00395-002-0365-8.
49. Gray, M. O.; Long, C. S.; Kalinyak, J. E.; Li, H. T.; & Karliner, J. S. (1998). Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovascular Research, 40(2), 352-363.
50. Adiarto, S.; Heiden, S.; Vignon-Zellweger, N.; Nakayama, K.; Yagi, K.; Yanagisawa, M.; & Emoto, N. (2012). ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy. Life Sciences. doi: 10.1016/j.lfs.2012.02.006.
51. Harada, M.; Itoh, H.; Nakagawa, O.; Ogawa, Y.; Miyamoto, Y.; Kuwahara, K.; Ogawa, E.; Igaki, T.; Yamashita, J.; Masuda, I.; Yoshimasa, T.; Tanaka, I.; Saito, Y.; & Nakao, K. (1997). Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: Evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation, 96(10), 3737-3744.
52. Widyantoro, B.; Emoto, N.; Nakayama, K.; Anggrahini, D. W.; Adiarto, S.; Iwasa, N.; Yagi, K.; Miyagawa, K.; Rikitake, Y.; Suzuki, T.; Kisanuki, Y. Y.; Yanagisawa, M.; & Hirata, K. (2010). Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation, 121(22), 2407-2418. doi: 10.1161/CIRCULATIONAHA.110.938217.
53. Kukreja, R. C.; Yin, C.; & Salloum, F. N. (2011). MicroRNAs: New players in cardiac injury and protection. Molecular Pharmacology, 80(4), 558-564. doi: 10.1124/mol.111.073528.
54. Sun, H.; & Wang, Y. (2011). Restriction of big hearts by a small RNA. Circulation Research, 108(3), 274-276. doi: 10.1161/CIRCRESAHA.110.239426.
55. Tijsen, A. J.; Pinto, Y. M.; & Creemers, E. E. (2012). Non-cardiomyocyte microRNAs in heart failure. Cardiovascular Research, 93(4), 573-582. doi: 10.1093/cvr/cvr344.
56. van Rooij, E.; & Olson, E. N. (2007). microRNAs put their signatures on the heart. Physiological Genomics, 31(3), 365-366. doi: 10.1152/ physiolgenomics.00206.2007.
57. van Rooij, E.; & Olson, E. N. (2007). MicroRNAs: Powerful new regulators of heart disease and provocative therapeutic targets. The Journal of Clinical Investigation, 117(9), 2369-2376. doi: 10.1172/JCI33099.
58. Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kissler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; Castoldi, M.; Soutschek, J.; Koteliansky, V.; Rosenwald, A.; Basson, M. A.; Licht, J. D.; Pena, J. T.; Rouhanifard, S. H.; Muckenthaler, M. U.; Tuschl, T.; Martin, G. R.; Bauersachs, J.; & Engelhardt, S. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 456(7224), 980-984. doi: 10.1038/nature07511.
59. Cheng, Y.; Zhu, P.; Yang, J.; Liu, X.; Dong, S.; Wang, X.; Chun, B.; Zhuang, J.; & Zhang, C. (2010). Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovascular Research, 87(3), 431-439. doi: 10.1093/cvr/cvq082.
60. Fleissner, F.; Jazbutyte, V.; Fiedler, J.; Gupta, S. K.; Yin, X.; Xu, Q.; Galuppo, P.; Kneitz, S.; Mayr, M.; Ertl, G.; Bauersachs, J.; & Thum, T. (2010). Short communication: Asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circulation Research, 107(1), 138-143. doi: 10.1161/CIRCRESAHA.110.216770.
61. Sabatel, C.; Cornet, A. M.; Tabruyn, S. P.; Malvaux, L.; Castermans, K.; Martial, J. A.; & Struman, I. (2010). Sprouty1, a new target of the angiostatic agent 16 K prolactin, negatively regulates angiogenesis. Molecular Cancer, 9, 231. doi: 10.1186/1476-4598-9-231.
62. Caporali, A.; & Emanueli, C. (2012). MicroRNAs in postischemic vascular repair. Cardiology Research and Practice, 2012, 486702. doi: 10.1155/2012/486702.
63. Fish, J. E.; & Srivastava, D. (2009). MicroRNAs: Opening a new vein in angiogenesis research. Science Signaling, 2(52), pe1. doi: 10.1126/scisignal.252pe1.
64. Fish, J. E.; Santoro, M. M.; Morton, S. U.; Yu, S.; Yeh, R. F.; Wythe, J. D.; Ivey, K. N.; Bruneau, B. G.; Stainier, D. Y.; & Srivastava, D. (2008). miR-126 regulates angiogenic signaling and vascular integrity. Developmental Cell, 15(2), 272-284. doi: 10.1016/j.devcel.2008.07.008.
65. Bonauer, A.; Carmona, G.; Iwasaki, M.; Mione, M.; Koyanagi, M.; Fischer, A.; Burchfield, J.; Fox, H.; Doebele, C.; Ohtani, K.; Chavakis, E.; Potente, M.; Tjwa, M.; Urbich, C.; Zeiher, A. M.; & Dimmeler, S. (2009). MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science, 324(5935), 1710-1713. doi: 10.1126/science.1174381.
66. Wang, S.; & Olson, E. N. (2009). AngiomiRs - Key regulators of angiogenesis. Current Opinion in Genetics and Development, 19(3), 205-211. doi: 10.1016/j.gde.2009.04.002.
67. Fish, J. E. (2012). A primer on the role of microRNAs in endothelial biology and vascular disease. Seminars in Nephrology, 32(2), 167-175. doi: 10.1016/j.semnephrol.2012.02.003.
68. Das, S.; Ferlito, M.; Kent, O. A.; Fox-Talbot, K.; Wang, R.; Liu, D.; Raghavachari, N.; Yang, Y.; Wheelan, S. J.; Murphy, E.; & Steenbergen, C. (2012). Nuclear miRNA regulates the mitochondrial genome in the heart. Circulation Research, 110(12), 1596-1603. doi: 10.1161/CIRCRESAHA.112.267732.
69. McCurley, A.; & Jaffe, I. Z. (2012). Mineralocorticoid receptors in vascular function and disease. Molecular and Cellular Endocrinology, 350(2), 256-265. doi: 10.1016/j.mce.2011.06.014.
70. Dagenais, G. R.; Yusuf, S.; Bourassa, M. G.; Yi, Q.; Bosch, J.; Lonn, E. M.; Kouz, S.; & Grover, J. (2001). Effects of ramipril on coronary events in high-risk persons: Results of the heart outcomes prevention evaluation study. Circulation, 104(5), 522-526.
71. Dahlof, B.; Devereux, R. B.; Kjeldsen, S. E.; Julius, S.; Beevers, G.; de Faire, U.; Fyhrquist, F.; Ibsen, H.; Kristiansson, K.; Lederballe-Pedersen, O.; Lindholm, L. H.; Nieminen, M. S.; Omvik, P.; Oparil, S.; & Wedel, H. (2002). Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet, 359(9311), 995-1003. doi: 10.1016/S0140-6736(02)08089-3.
72. Zanchetti, A.; Hansson, L.; Dahlof, B.; Elmfeldt, D.; Kjeldsen, S.; Kolloch, R.; Larochelle, P.; McInnes, G. T.; Mallion, J. M.; Ruilope, L.; & Wedel, H. (2001). Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension, 19(6), 1149-1159.
73. Zannad, F.; McMurray, J. J.; Krum, H.; van Veldhuisen, D. J.; Swedberg, K.; Shi, H.; Vincent, J.; Pocock, S. J.; & Pitt, B. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. The New England Journal of Medicine, 364(1), 11-21. doi: 10.1056/NEJMoa1009492.
74. Lonn, E.; Yusuf, S.; Dzavik, V.; Doris, C.; Yi, Q.; Smith, S.; Moore-Cox, A.; Bosch, J.; Riley, W.; & Teo, K. (2001). Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation, 103(7), 919-925.
75. Guder, G.; Bauersachs, J.; Frantz, S.; Weismann, D.; Allolio, B.; Ertl, G.; Angermann, C. E.; & Stork, S. (2007). Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation, 115(13), 1754-1761. doi: 10.1161/CIRCULATIONAHA.106.653964.
76. Mizuno, Y.; Yoshimura, M.; Yasue, H.; Sakamoto, T.; Ogawa, H.; Kugiyama, K.; Harada, E.; Nakayama, M.; Nakamura, S.; Ito, T.; Shimasaki, Y.; Saito, Y.; & Nakao, K. (2001). Aldosterone production is activated in failing ventricle in humans. Circulation, 103(1), 72-77.
77. Fraccarollo, D.; Berger, S.; Galuppo, P.; Kneitz, S.; Hein, L.; Schutz, G.; Frantz, S.; Ertl, G.; & Bauersachs, J. (2011). Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation, 123(4), 400-408. doi: 10.1161/CIRCULATIONAHA.110. 983023.
78. Lother, A.; Berger, S.; Gilsbach, R.; Rosner, S.; Ecke, A.; Barreto, F.; Bauersachs, J.; Schutz, G.; & Hein, L. (2011). Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension, 57(4), 746-754. doi: 10.1161/HYPERTENSIONAHA.110.163287.
79. Bienvenu, L. A.; Morgan, J.; Rickard, A. J.; Tesch, G. H.; Cranston, G. A.; Fletcher, E. K.; Delbridge, L. M.; & Young, M. J. (2012). Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology, 153(7), 3416-3425. doi: 10.1210/en.2011-2098.
80. Cox, M. J.; Sood, H. S.; Hunt, M. J.; Chandler, D.; Henegar, J. R.; Aru, G. M.; & Tyagi, S. C. (2002). Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. American Journal of Physiology-Heart and Circulatory Physiology, 282(4), H1197-H1205. doi: 10.1152/ajpheart.00483.2001.
81. Givvimani, S.; Qipshidze, N.; Tyagi, N.; Mishra, P. K.; Sen, U.; & Tyagi, S. C. (2011). Synergism between arrhythmia and hyperhomocysteinemia in structural heart disease. International Journal of Physiology Pathophysiology Pharmacology, 3(2), 107-119.
82. Hunt, M. J.; Aru, G. M.; Hayden, M. R.; Moore, C. K.; Hoit, B. D.; & Tyagi, S. C. (2002). Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. American Journal of Physiology. Lung Cellular and Molecular Physiology, 283(2), L239-L245. doi: 10.1152/ajplung.00001.2002.
83. Moshal, K. S.; Kumar, M.; Tyagi, N.; Mishra, P. K.; Metreveli, N.; Rodriguez, W. E.; & Tyagi, S. C. (2009). Restoration of contractility in hyperhomocysteinemia by cardiac-specific deletion of NMDA-R1. American Journal of Physiology-Heart and Circulatory Physiology, 296(3), H887-H892. doi: 10.1152/ajpheart.00750.2008.
84. Ovechkin, A. V.; Tyagi, N.; Rodriguez, W. E.; Hayden, M. R.; Moshal, K. S.; & Tyagi, S. C. (2005). Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. Journal of Applied Physiology, 99(6), 2398-2405. doi: 10.1152/japplphysiol.00442.2005.
85. Narmoneva, D. A.; Vukmirovic, R.; Davis, M. E.; Kamm, R. D.; & Lee, R. T. (2004). Endothelial cells promote cardiac myocyte survival and spatial reorganization: Implications for cardiac regeneration. Circulation, 110(8), 962-968. doi: 10.1161/01.CIR.0000140667.37070.0701.CIR.0000140667.37070.07.
86. Christalla, P.; Hudson, J. E.; & Zimmermann, W. H. (2012). The cardiogenic niche as a fundamental building block of engineered myocardium. Cells, Tissues, Organs, 195(1-2), 82-93. doi: 10.1159/000331407.
87. Schaaf, S.; Shibamiya, A.; Mewe, M.; Eder, A.; Stohr, A.; Hirt, M. N.; Rau, T.; Zimmermann, W. H.; Conradi, L.; Eschenhagen, T.; & Hansen, A. (2011). Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One, 6(10), e26397. doi: 10.1371/journal.pone. 0026397PONE-D-11-08333.
88. Seif-Naraghi, S. B.; Salvatore, M. A.; Schup-Magoffin, P. J.; Hu, D. P.; & Christman, K. L. (2010). Design and characterization of an injectable pericardial matrix gel: A potentially autologous scaffold for cardiac tissue engineering. Tissue Engineering. Part A, 16(6), 2017-2027. doi: 10.1089/ten.TEA.2009.0768.
89. Yamada, Y.; Yokoyama, S.; Fukuda, N.; Kidoya, H.; Huang, X. Y.; Naitoh, H.; Satoh, N.; & Takakura, N. (2007). A novel approach for myocardial regeneration with educated cord blood cells cocultured with cells from brown adipose tissue. Biochemical and Biophysical Research Communications, 353(1), 182-188. doi: 10.1016/j.bbrc.2006.12.017.
90. Zimmermann, W. H. (2009). Remuscularizing failing hearts with tissue engineered myocardium. Antioxidants & Redox Signaling, 11(8), 2011-2023. doi: 10.1089/ARS.2009.2467.
91. He, W.; Ye, L.; Li, S.; Liu, H.; Wu, B.; Wang, Q.; Fu, X.; Han, W.; & Chen, Z. (2012). Construction of vascularized cardiac tissue from genetically modified mouse embryonic stem cells. The Journal of Heart and Lung Transplantation, 31(2), 204-212. doi: 10.1016/j.healun.2011.11.010.
92. Naito, H.; Melnychenko, I.; Didie, M.; Schneiderbanger, K.; Schubert, P.; Rosenkranz, S.; Eschenhagen, T.; & Zimmermann, W. H. (2006). Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation, 114(1 Suppl), I72-I78. doi: 10.1161/CIRCULATIONAHA.105.001560.
93. Stevens, K. R.; Kreutziger, K. L.; Dupras, S. K.; Korte, F. S.; Regnier, M.; Muskheli, V.; Nourse, M. B.; Bendixen, K.; Reinecke, H.; & Murry, C. E. (2009). Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proceedings of the National Academy of Science U S A, 106(39), 16568-16573. doi: 10.1073/pnas.0908381106.
94. Koffler, J.; Kaufman-Francis, K.; Shandalov, Y.; Egozi, D.; Pavlov, D. A.; Landesberg, A.; & Levenberg, S. (2011). Improved vascular organization enhances functional integration of engineered skeletal muscle grafts. Proceedings of the National Academy of Science U S A, 108(36), 14789-14794. doi: 10.1073/pnas.1017825108.
95. Banerjee, I.; Fuseler, J. W.; Price, R. L.; Borg, T. K.; & Baudino, T. A. (2007). Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. American Journal of Physiology - Heart and Circulatory Physiology, 293(3), H1883-H1891. doi: 10.1152/ajpheart.00514. 2007.
96. Shiojima, I.; Sato, K.; Izumiya, Y.; Schiekofer, S.; Ito, M.; Liao, R.; Colucci, W. S.; & Walsh, K. (2005). Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. The Journal of Clinical Investigation, 115(8), 2108-2118. doi: 10.1172/JCI24682.
97. Zavadil, J.; Bitzer, M.; Liang, D.; Yang, Y. C.; Massimi, A.; Kneitz, S.; Piek, E.; & Bottinger, E. P. (2001). Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proceedings of the National Academy of Science U S A, 98(12), 6686-6691. doi: 10.1073/pnas. 11161439898/12/6686.
98. Markwald, R. R.; Fitzharris, T. P.; & Smith, W. N. (1975). Sturctural analysis of endocardial cytodifferentiation. Developmental Biology, 42(1), 160-180.
99. Kovacic, J. C.; Mercader, N.; Torres, M.; Boehm, M.; & Fuster, V. (2012). Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: From cardiovascular development to disease. Circulation, 125(14), 1795-1808. doi: 10.1161/CIRCULATIONAHA.111.040352.
100. Piera-Velazquez, S.; Li, Z.; & Jimenez, S. A. (2011). Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. American Journal of Pathology, 179(3), 1074-1080. doi: 10.1016/j.ajpath.2011.06.001.
101. von Gise, A.; & Pu, W. T. (2012). Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circulation Research, 110(12), 1628-1645. doi: 10.1161/CIRCRESAHA.111.259960.
102. van Meeteren, L. A.; & ten Dijke, P. (2012). Regulation of endothelial cell plasticity by TGF-beta. Cell and Tissue Research, 347(1), 177-186. doi: 10.1007/s00441-011-1222-6.
103. Goumans, M. J.; Valdimarsdottir, G.; Itoh, S.; Rosendahl, A.; Sideras, P.; & ten Dijke, P. (2002). Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO Journal, 21(7), 1743-1753. doi: 10.1093/emboj/21.7.1743.
104. Goumans, M. J.; van Zonneveld, A. J.; & ten Dijke, P. (2008). Transforming growth factor beta-induced endothelial-to-mesenchymal transition: A switch to cardiac fibrosis? Trends in Cardiovascular Medicine, 18(8), 293-298. doi: 10.1016/j.tcm.2009.01.001.
105. Medici, D.; Shore, E. M.; Lounev, V. Y.; Kaplan, F. S.; Kalluri, R.; & Olsen, B. R. (2010). Conversion of vascular endothelial cells into multipotent stem-like cells. Nature Medicine, 16(12), 1400-1406. doi: 10.1038/nm.2252.
106. Ghosh, A. K.; & Vaughan, D. E. (2011). PAI-1 in tissue fibrosis. Journal of Cellular Physiology. doi: 10.1002/jcp.22783.
107. Lopez, D.; Niu, G.; Huber, P.; & Carter, W. B. (2009). Tumor-induced upregulation of Twist, Snail, and Slug represses the activity of the human VE-cadherin promoter. Archives of Biochemistry and Biophysics, 482(1-2), 77-82. doi: 10.1016/j.abb.2008.11.016.
108. Cano, A.; Perez-Moreno, M. A.; Rodrigo, I.; Locascio, A.; Blanco, M. J.; del Barrio, M. G.; Portillo, F.; & Nieto, M. A. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology, 2(2), 76-83. doi: 10.1038/35000025.
109. Feng, X. H.; & Derynck, R. (2005). Specificity and versatility in tgf-beta signaling through Smads. Annual Review of Cell and Developmental Biology, 21, 659-693. doi: 10.1146/annurev.cellbio.21.022404.142018.
110. Luo, Y.; & Radice, G. L. (2005). N-cadherin acts upstream of VE-cadherin in controlling vascular morphogenesis. The Journal of Cell Biology, 169, 29-34. doi: 10.1083/jcb.200411127.